COMPASS THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
COMPASS THERAPEUTICS, INC. (CMPX) reported Increase (Decrease) in Accrued Liabilities of $202.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $3.58M.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$3.38M, a 148.84% decline year-over-year.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.70M, a 19.93% decline year-over-year.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$2.31M.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $5.10M, a 35.06% increase from fiscal 2024.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $3.77M.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was -$9.18M, a 414.79% decline from fiscal 2022.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $2.92M, a 58.45% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $202.00K 10-Q · filed 2026-08-06 | $2.90M derived: sum of 3 quarters · filed 2026-08-06 | $593.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.38M 10-Q · filed 2026-05-05 | -$684.00K derived: sum of 2 quarters · filed 2026-05-05 | -$2.99M derived: sum of 3 quarters · filed 2026-05-05 | -$5.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $391.00K derived: sum of 2 quarters · filed 2026-03-05 | -$1.83M derived: sum of 3 quarters · filed 2026-08-06 | $5.10M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$4.53M derived: sum of 2 quarters · filed 2026-08-06 | $2.40M 10-Q · filed 2025-11-05 | $5.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.71M 10-Q · filed 2026-08-06 | $8.08M derived: sum of 3 quarters · filed 2026-08-06 | $3.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.93M 10-Q · filed 2026-05-05 | $10.30M derived: sum of 2 quarters · filed 2026-05-05 | $5.99M derived: sum of 3 quarters · filed 2026-05-05 | $11.40M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$940.00K derived: sum of 2 quarters · filed 2026-03-05 | $4.47M derived: sum of 3 quarters · filed 2026-03-05 | $3.77M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$4.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.10M derived: sum of 2 quarters · filed 2025-11-05 | $402.00K 10-Q · filed 2025-11-05 | -$2.73M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $5.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $4.71M 10-Q · filed 2025-08-11 | $1.58M derived: sum of 3 quarters · filed 2025-08-11 | -$600.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$699.00K 10-Q · filed 2025-05-08 | -$3.83M derived: sum of 2 quarters · filed 2025-05-08 | -$6.01M derived: sum of 3 quarters · filed 2025-05-08 | -$7.13M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$5.31M derived: sum of 2 quarters · filed 2025-02-27 | -$6.43M derived: sum of 3 quarters · filed 2025-02-27 | -$9.18M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$3.30M derived: sum of 2 quarters · filed 2024-11-12 | -$6.05M 10-Q · filed 2024-11-12 | -$98.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$3.86M 10-Q · filed 2024-08-12 | $2.08M derived: sum of 3 quarters · filed 2024-08-12 | $5.04M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$2.75M 10-Q · filed 2024-05-13 | $3.20M derived: sum of 2 quarters · filed 2024-05-13 | $6.16M derived: sum of 3 quarters · filed 2024-05-13 | $763.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $5.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $8.90M derived: sum of 2 quarters · filed 2024-03-21 | $3.51M derived: sum of 3 quarters · filed 2024-03-21 | $2.92M 10-K · filed 2024-03-21 |
| 2022-09-30 | $2.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.44M derived: sum of 2 quarters · filed 2023-11-09 | -$3.03M 10-Q · filed 2023-11-09 | $3.56M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$5.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$5.99M 10-Q · filed 2023-08-03 | $602.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.43M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$595.00K 10-Q · filed 2023-05-04 | $5.99M derived: sum of 2 quarters · filed 2023-05-04 | $6.82M derived: sum of 3 quarters · filed 2023-05-04 | $6.86M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $6.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $7.41M derived: sum of 2 quarters · filed 2023-03-15 | $7.46M derived: sum of 3 quarters · filed 2023-03-15 | $7.02M 10-K · filed 2023-03-15 |
| 2021-09-30 | $825.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $869.00K derived: sum of 2 quarters · filed 2022-11-09 | $427.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$398.00K 10-Q · filed 2021-08-16 | ||
| 2021-06-20 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | -$398.00K 10-Q · filed 2022-08-01 | -$101.00K derived: sum of 3 quarters · filed 2022-08-01 | $49.00K derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-03-31 | -$442.00K 10-Q · filed 2022-05-09 | -$145.00K derived: sum of 2 quarters · filed 2022-05-09 | $5.00K derived: sum of 3 quarters · filed 2022-05-09 | $79.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $447.00K derived: sum of 2 quarters · filed 2022-03-18 | $521.00K derived: sum of 3 quarters · filed 2022-03-18 | -$1.55M 10-K · filed 2022-03-18 |
| 2020-09-30 | $150.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $224.00K derived: sum of 2 quarters · filed 2021-11-12 | -$1.85M 10-Q · filed 2021-11-12 | -$1.74M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$2.00M 10-Q · filed 2021-08-16 | -$1.89M derived: sum of 3 quarters · filed 2021-08-16 | -$1.66M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$2.07M 10-Q · filed 2021-04-30 | -$1.96M derived: sum of 2 quarters · filed 2021-04-30 | -$1.74M derived: sum of 3 quarters · filed 2021-04-30 | |
| 2019-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $336.00K derived: sum of 2 quarters · filed 2021-03-05 | $509.00K 10-K · filed 2021-03-05 | |
| 2019-09-30 | $228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $401.00K 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $173.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |